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CryptosporidiumPs) from amphibians and other eukaryotes recognize pathogenicity patterns
mostly related to differences in membrane composition between the host and a variety of bacterial, fungal
and protozoan pathogens. Compared to the other two groups, protozoa are fairly neglected targets in
antimicrobial chemotherapy, despite their role as causative agents for scourges such as malaria, amoebiasis,
Chagas' disease or leishmaniasis. Herein we review the scarce but growing body of knowledge addressing the
use of amphibian AMPs on parasitic protozoa, the adaptations of the protozoan to AMP pressure and their
impact on AMP efﬁcacy and speciﬁcity, and the current and foreseeable strategies for developing AMPs into
practical therapeutic alternatives against parasitic disease.
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ll rights reserved.1. Introduction: Protozoa as neglected target for AMPs
Antimicrobial peptides (AMPs) constitute a ﬁrst barrier against
pathogen dissemination in pluricellular organisms (see reviews [1–
3]). As components of the innate immunity, they are able to act on a
wide variety of pathogens, including Protozoa. Nevertheless, this
group of microorganisms has received much less attention as a target
for AMPs than pathogens such as bacteria or fungi. There are several
causes for this relative neglect: i) the fact that pathogenic potential of
Protozoa affects by and large the tropical and subtropical areas of the
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given lowpriority to research investment by the pharmaceutical sector
on devastating diseases such as malaria, leishmaniasis, or trypanoso-
miasis. While this situation has of late been partially ameliorated by
partnerships among pharma industry, WHO, charities and academia
[4], the development of anti-protozoan drugs still lags behind those
addressing other infectious diseases [5]. ii) AMP production costs,
about a log higher than for small molecule antibiotics, act as a brake on
the development of clinical trials and ultimately therapeutic
approaches. iii) While HIV-associated parasitic infections with worri-
some mortality and morbidity rates (e.g., Cryptosporidium or Leish-
mania) have raised obvious concerns, they appear to bemanageable by
HAART therapy [6]. iv) A sizable gap in both basic knowledge and
research tools penalizes Protozoa vs. other microbial or mammalian
systems. For instance, techniques such as axenic culture methods have
not been available for many parasitic protozoa until recently,
substantially restricting the availability of microorganisms for sys-
tematic testing. v) The peculiarities of protozoan molecular biology
preclude the use of otherwise highly effective approaches (e.g., RNAi in
Leishmania) in the testing of different targets. vi) A further negative
factor is the variety of protozoan groups, with complex life-cycles that
often involvemultiple stageswith dramatic differences inmetabolism,
protein expression and, relevant for AMP, membrane composition. vii)
Additionally, some of these stages entail intracellular hiding of the
parasite, or at least impaired access of external AMPs. viii) Finally, the
expression and action of autologous AMPs in either commensal or
parasitic Protozoa is a completely unexplored ﬁeld.
Despite these difﬁculties, Protozoa remain a highly appealing
model for AMP research: a typical protozoan infection requires several
weeks to reach its ﬁnal stage, vs. the much faster pace of bacterial
infections with generation times at least a log order lower than
Protozoa. This explains why these microorganisms have been
portrayed as master subverters of the host immune response, their
subversionmore pronounced at some stages in the invertebrate vector
or the vertebrate host where AMP might be relevant.
2. Mechanism of action of AMPs
For the beneﬁt of readers unfamiliar with the subject, this review
leads off with an outline of the mechanism of action of AMPs. For a
broader appreciation of the ﬁeld, and to avoid constant reference to
other reviews, AMPs other than amphibian are occasionally discussed,
and partial overlap with other reviews in this issue is minimized but
not totally avoided.
Antiprotozoal activities of natural amphibian AMPs are shown in
Table 1. As different microbicidal parameters are used by different
authors, the percent microbicidal activity at a given concentration is
given. As usual with AMPs, most activities are in the micromolar
range. As most AMPs hitherto described, amphibian AMPs are strongly
cationic; of 210 entries in the AMSDb database (http://www.bbcm.
univ.trieste.it/∼tossi/pag2.htm) under the amphibian subcategory,
only maximin H5 from Bombina maxima is anionic. While amphibian
AMPs display a wide range of structural motifs (α-helical, Gly-rich
with high conformational ﬂexibility, e.g., plasticins; disulﬁde-bridged
or even heteromeric), studies on protozoan targets focus mainly on
dermaseptins, and to a lesser extent on magainins, phylloseptins and
ranalexins, the latter an example of non-linear, internal disulﬁde-
linked structure.
Broadly speaking, two major mechanisms of AMP action exist. The
most general one refers to AMPs for which membrane permeabiliza-
tion leads to pathogen death [7]. In an alternative mechanism, the
AMP enters the cytoplasm as above, but killing relies on an
intracellular target [8]. In either mechanism, two salient structural
features of AMPs, cationic character and amphipathicity, underpin
recognition of so called pathogen-associated molecular patterns
(PAMPs), common to a wide set of pathogens, in the context of theinnate immune response where AMPs belong. These features mainly
refer to the ability of AMPs to exploit differences in lipid composition
of the pathogen (vs. vertebrate host) plasmamembrane (PM). The PM
of prokaryotes and lower eukaryotes is characterized by the presence
of anionic phospholipids (PLs) at the outer leaﬂet, by the content (or
absence) of certain sterols, and to a lesser extent by a distinctive
plasma membrane potential (see Section 3 for further details).
Morphological (see Fig. 1) and functional assays conﬁrm that
membrane permeabilization is achieved by distortion of the PM
structure, not by activation of a pre-existing pore or transporter. The
ensuing effects, which depend on AMP and the severity of the damage,
usually include dissipation of ionic gradients across the PM, leakage of
nutrients and/or larger cytoplasmic components, and ﬁnally a
collapse of the parasite bioenergetics and osmotic lysis. This killing
mechanism, usually quite fast and causing reduction of log orders of
pathogens in a fewminutes, does not involve any chiral requirements,
as all-D-enantiomers of AMPs perform similarly to the native versions
[9]. Moreover, as it is based on simple physico-chemical rather than
receptor-speciﬁc interactions, this mechanism does not favor the
appearance of resistance, which requires substantial changes in
phospholipid composition. Other resistance strategies, such as
proteinase production, are equally thwarted due to the fast kinetics
of the process. In fact, most resistance traits described for AMPs on
Protozoa rely on the existence of extracellular barriers largely
impervious to AMPs such as the wall structure of some cyst stages
(see Section 3.3). Unfortunately, the current knowledge on overall
composition and asymmetric distribution of phospholipids in Proto-
zoa is very limited (see review in [10]). Most models accounting for
AMP-induced membrane permeation are inferred from data obtained
with model phospholipid mono- or bilayers. These simpliﬁed models
entail substantial caveats, such as (i) the lack of proteins with
important roles in molecular crowding or formation or maintenance
of lipid domains, or (ii) the incomplete reproduction of natural bilayer
characteristics not strictly related to membrane proteins, such as
phospholipid asymmetry. Thus, extrapolation from an in vitro to an in
vivo model of PM permeation mechanism is not straightforward.
The main models advanced for PM permeation range from a
canonical trans-membrane pore (barrel-stave), to solubilization of the
membrane by a detergent-like action, based on the amphipathic
character of the AMPs and their massive accumulation into the
membrane (carpet-like model) (Fig. 2) [7,11,12]. The barrel-stave
model of PM permeation predicts membrane permeation at very low
peptide:phospholipid ratio, assuming that peptide–peptide interac-
tion is stronger than peptide–phospholipid. The model also entails,
ﬁrst, a scarce modiﬁcation of the overall physical parameters of the
bilayer, and secondly, poor selectivity of pore formation with respect
to membrane composition. Moreover, if a strict peptide stoichiometry
is required for pore formation, an upper size limit for the leakiness of
molecules is imposed, at least in the ﬁrst steps of themechanism prior
to osmotic lysis. In the opposite carpet-like model the AMP, due to its
cationic character, accumulates massively in the in-plane interfacial
region of the outer leaﬂet of the PM, where monomer–monomer
electrostatic repulsion is quenched by the anionic phospholipids. A
calculation of this model based on the insect AMP cecropin A, taking
into account peptide dimension and bacterial size, concluded that the
AMPs practically must cover the whole organism in order to kill it [13]
(Fig. 2B). Once a threshold accumulation is reached, the membrane is
solubilized [14]. The intermediate worm-hole or two-state model
proposed independently by Matsuzaki and Huang (reviewed in [7])
tries to reconcile three experimental observations: i) the change in
orientation undergone by a fraction of membrane-bound peptide once
a threshold is reached, ii) peptide-induced phospholipid ﬂip-ﬂop, and
iii) peptide translocation into the cytoplasm, a fact ignored by the two
previous models. In this model themassive union of the AMPs into the
external monolayer of the PM leads to its expansion, causing a
mechanical stress. Once a threshold is reached, a fraction of the
Table 1
Activity of amphibian antimicrobial peptides on Protozoa
Peptidea Sequence Protozoan specie (stage)b Microbicidal effect Comments References
Inhibition (%) [Peptide] (μM)
PGLa GMASKAGAIAGKIAKVALKA-NH2 Plasmodium falciparum
(tph+sch)c
50 40 Inhibition of RBC
reinvasion
[138]
Paramecium caudatum 100 2.7 Cell disruption, [139]
Tetrahymena pyriformis 100 10.8 q [139]
Acanthamoeba castellanii (tph) 100 1.0 q [139]
Xenopsin GWASKIGQTLGKIAKVGLKELIQPK P. caudatum 100 3.8 q [139]
T. pyriformis 100 7.6 q [139]
A. castellanii (tph) 100 0.75 q [139]
Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS P. caudatum 100 4.1 Cell disruption, [139,140]
T. pyriformis 100 8.1 q [139]
A. castellanii 100 0.9 q [139]
P. falciparum (tph+sch) 90 100 Inhibition of RBC
reinvasion
[138]
Cryptosporidium parvum
(spo+ooc)c
39.2 50 [34]
Magainin
2-amidated
GIGKFLHSAKKFGKAFVGEIMNS-NH2 Plasmodium cynomolgi 94 0.1 nmol/mosquito Inhibition of oocyst
formation in Anopheles
after peptide inoculation
[136]
Plasmodium knowlesi 95 q
P. falciparum 86 q
Buforin 2 TRSSRAGLQFPVGRVHRLLRK C. parvum (spo) 100 4 After 3 h incubation [34]
(ooc) 29 40 q
C. parvum (mer+gam)c 55.7 20 After 48 h incubation [60]
Ranalexin-1CB C. parvum (mer+gam)c 42 50 Inhibition of intracellular
growth in A549 cells
[61]
Dermaseptin-S1
(DRS-S1)
ALWKTMLKKLGTMALHAGKAALGA-
AADTISQGTQ
Leishmania major (pro) 50 4.5 After 3 h incubation [141]
Leishmania mexicana (pro) 50 1.5 MIC after 48h [142,144]
100 4.3 q
Dermaseptin-S3
(DRS-S3)
ALWKNMLKGIGKLAGKAALGAVKKLVGAES P. falciparum (i. f.) 50 0.3–1.5 Range of LC50 depending
on the strain tested
[47]
Dermaseptin-S4
(DRS-S4)
ALWMTLLKKVLKAAAKALNAVLVGANA P. falciparum (tph) 50 1.2 50% hemolysis at 1.4 μM [46]
L. major (pro) 50 1.5–2.0 [9,79,141]
Dermaseptin-O1
DRS-O1
GLWSTIKQKGKEAAIAAAKAAGQAALGAL-NH2 Trypanosoma cruzi (try) 100 2.8 After 2 h incubation [143]
Leishmania amazonensis (pro) 20 11.6 Biphasic killing [145]
100 23.4 q
Dermaseptin-H3
(DRS-H3)
GLWSTIKNVGKEAAIAAGKAALGAL-NH2 L. amazonensis (pro) 78 13.5 Biphasic killing [145]
100 27.0
Dermaseptin-DI2
(DRS-DI2)
ALWKTLLKNVGKAAGKAALNAVTDMVNQ T. cruzi (try) 100 2.7 After 2 h incubation [143]
Dermaseptin-DI1
(DRS-DI1)
GLWSKIKAAGKEAAKAAAKAAGKAALN-
AVSEAV
T. cruzi (try) 100 2.5 q [143]
Bombinin H2 IIGPVLGLVGSALGGLLKKI-NH2 Leishmania donovani (pro) 50 7.3 Inhibition of cell
proliferation
[41]
Leishmania pifanoi (ama) 50 11.0 q [41]
Bombinin H4 IiGPVLGLVGSALGGLLKKI-NH2d L. donovani (pro) 50 1.7 q [41]
L. pifanoi (ama) 50 5.6 q [41]
Temporin A FLPLIGRVLSGIL-NH2 L. donovani (pro) 50 8.4 q [44]
L. pifanoi (ama) 50 14.6 q [44]
Temporin B LLPIVGNLLKSLL-NH2 L. donovani (pro) 50 8.6 q [44]
L. pifanoi (ama) 50 7.1 q [44]
Temporin-1Sa FLSGIVGMLGKLF-NH2 Leishmania infantum
(pro)
50 18.1 Inhibition of cell
proliferation
[146]
(ama) 50 22.8
Phylloseptin O1
(PLS-O1)
FLSLIPHAINAVSTLVHHSG-NH2 T. cruzi (try) 50 5.1 q [147]
Phylloseptin O2
(PLS-O2)
FLSLIPHAINAVSAIAKHS-NH2 T. cruzi (try) 50 4.9 q [147]
Skin peptide YY YPPKPESPGEDASPEEMNKYLTALRHYINL-
VTRQRY-NH2
L. major (pro) 100 5.9 Faster killing of
promastigotes
[148]
(ama) 100 6.2
a The new peptide nomenclature proposed in Refs. [149,150] was adopted.
b Abbreviations: ama, amastigote; epi, epimastigote; gam: gamont; i.f., intracellular forms; mer, meront; ooc: oocyst; pro, promastigote; RBC, erythrocytes (red blood cell); sch:
schyzont; spo: sporozoite; tph, trophozoite; try, trypomastigote.
c No differentiation between both stages was carried out.
d - i .- Stands for D-allo-isoleucine.
1572 L. Rivas et al. / Biochimica et Biophysica Acta 1788 (2009) 1570–1581peptides lying parallel to the plane of the membrane change their
orientation from parallel to transversal, promoting a positive
curvature of the membrane and forming a mixed phospholipid–peptide toroidal pore where the hydrophobic lining is provided both
by the polar heads of the phospholipids plus the hydrophilic face of
the peptides. This pore also acts as catalyst for phospholipid
Fig. 1. Electron microscopy micrographs of Leishmania pifanoi amastigotes treated with amphibian antimicrobial peptides. Panels (A) control parasites; (B) 5 μM bombinin H4; (C)
7.5 μM temporin B. Magniﬁcation bar=0.5 μm. (Photo J.M. Saugar).
1573L. Rivas et al. / Biochimica et Biophysica Acta 1788 (2009) 1570–1581interchange between the two leaﬂets. This pore is transitory and,
when it disappears, stochastically sends its forming monomers to
either side of the membrane. This more comprehensive model
represents a subtle tour de force reﬁnement over the detergent
carpet-like model and may account for the step-wise increase in
conductivity observed for several AMPs. Still a fourth mechanism, the
“aggregate model” [7], relaxes the structural requirements intrinsic to
the toroidal model, mostly applicable to α-helical peptides, to
accommodate peptides not adopting this prototypical cylindrical
shape. Finally a ﬁfth model, the so called “Droste mechanism”, has
been proposed for melittin [15], where the toroidal lumen adopts a
poor orientation and hydrophilic lining is mostly provided by the
positive curvature of the phospholipids, with scarce protagonism of
the peptide, which accumulates at the rim of the pore and stabilizes it.
3. Defense systems by the parasite
Although Protozoa share most traits of AMP susceptibility and
resistance with microorganisms such as fungi or bacteria, there are
some speciﬁc aspects that deserve commentary.Fig. 2. Schematic representation of the three basic models of interaction of antimicrobial pept
themembrane, but differ in the following steps. The barrel-stavemodel (A) forms a classical p
in contact with the acyl chains of phospholipids. In the carpet like model (B), the peptide accu
The two-states or toroidal model (C) also starts as the carpet-like with massive peptide accu
by forcing some of the peptides to adopt a transmembrane orientation, forming a mixed pho
stochastical disruption, with relocation of the monomers at both sides of the membrane. (R3.1. Phospholipid composition
Like other lower eukaryotes, Protozoa expose acidic PLs at the
outer leaﬂet of the membrane, a feature that becomes a main
speciﬁcity factor for preferential lysis by AMPs. Model membrane
studies have brought forth a growing awareness that the speciﬁc
composition of the external phospholipidmonolayer, either anionic or
zwitterionic, can modulate to a signiﬁcant extent the ﬁnal outcome of
the permeation event for a given peptide. As the AMP inserts into the
external monolayer, the speciﬁc type and abundance of the outer PLs
imposes charge density and geometrical constraints that inﬂuence the
formation of the lytic structure. For instance, many AMPs promote a
positive curvature of the membrane so as to form a mixed
phospholipid–peptide pore, hence PLs with a tendency to promote a
negative curvature such as phosphatidylserine (PS) or phosphatidic
acid (PA), require a much higher peptide:lipid ratio than phosphati-
dylglycerol (PG) for permeabilization by magainin 2 [16].
Despite the scarcity of data on protozoan membrane PL composi-
tion and membrane asymmetry (see above), the presence of anionic
PLs may at times be inferred by the binding of cationic molecules. Forides (AMPs) with cellular membranes. All models share the initial binding of the AMP to
ore linedwith the polar face (red) of the peptidewhereas the hydrophobic one (blue) is
mulates massively at the membrane interphase, with ﬁnal disruption of the membrane.
mulation, but the mechanical tension created by the peptide accumulation was relieved
spholipid–peptide pore spanning the membrane; in a further step, the pore undergoes a
eprinted from Ref. [7] with permission, Copyright 2006, Elsevier).
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involved in the acquisition of virulence by promastigotes, an
enhancement of the external exposure of PS, a PL usually conﬁned
to the inner leaﬂet of the PM in eukaryotes, has been documented [17].
More importantly, the pathological form of Leishmania, i.e., the
amastigote, also exposes PS as part of a macrophage-deceiving
strategy which nonetheless might be exploited by leishmanicidal
AMPs [18].
The efﬁcacy of AMPs depends not only on the presence of speciﬁc
types of acidic PLs but also on a favorable overall composition, with
low levels of speciﬁc PLs detrimental to AMP action. For instance,
phosphatidylethanolamine (PE) is a well-known inhibitor of positive
curvature and as such severely impairs pore formation by magainin 2
[16], or suppresses buforin II membrane translocation [19]. An
inversion in the phosphatidylcholine (PC) PC:PE ratio upon treatment
with several antiparasitic drugs has been described for Trypanoso-
matidae, together with an increased PS exposure and with a possible
ensuing loss in the efﬁcacy of an AMP-based treatment (see Section 5).
Another insight into the modiﬁcation of AMP performance comes
from recent results on the possible role of oxidized PLs as preferential
targets for AMPs. Thus, incorporation of the oxidized PC analog 1-
palmitoyl-2-(9′-oxo-nonanoyl)-sn-glycero-3-phosphocholine (Pox-
noPC) into lipid monolayers increases temporin B and L insertion,
possibly by formation of a Schiff's base between the aldehyde group of
the oxidized PL and an amino group of the AMP [20]. This may be quite
relevant for parasites under oxidative stress, either from chemother-
apy or from the host immune response, such as Leishmania [21], Try-
panosoma [22], or the intraerythrocytic Plasmodium [23].
3.2. Sterols of the plasma membrane
The preferential activity of AMPs on prokaryotes vs. eukaryotes is
known to be partially dependent on the type and relative amount of
sterols in the PM [24]. In model membranes, cholesterol impairs
permeabilization by amphibian AMPmagainin 2 [25]. It also decreases
temporin L binding to liposomes [26], as well as the depth of
membrane penetration by AMPs [27] or GUV vesiculation [28]. At a
functional level, cholesterol depletion by cyclodextrin treatment
increases the toxicity of AMPs against mammalian cells [29].
Plasmodium and Cryptosporidium, which do not biosynthesize
sterols, totally depend on intake from the host to maintain sterol
levels in their membranes. In contrast, Trypanosomatidae can produce
ergosterol by a biosynthetic pathway similar to that of fungi [30].
Interestingly, the bulkier side chain of ergosterol relative to choles-
terol makes for poorer membrane packing and thereby weaker
inhibition of vesicle permeabilization [26]. It has also been reported
that ergosterol sensitizes DOPS membranes to magainin 2 permeabi-
lization [31]; a speciﬁc binding of the peptide to ergosterol has been
advanced, also proposed for dermaseptins [32].
3.3. Glycocalix and other external barriers to AMP action
Contrary to fungi or yeasts, Protozoa do not have a permanent cell
wall throughout their life cycle. For parasites with environmental
rather than vectorial transmission (e.g., Entamoeba, Giardia, Acantha-
moeba, Toxoplasma, Cryptosporidium), encystment is a practical option
to survive in harsh environments (e.g., nutritional deﬁcits) until a
suitable host for completing the cycle is available. Encystment is a
substantial hurdle to AMP action on Protozoa. For instance, the oocyst
of Cryptosporidium parvum [33], a parasite of signiﬁcant concern in
drink water treatment due to its low permeability to water-soluble
agents, is highly resistant to AMP action (Table 1) [34,35]. This
imperviousness to AMP activity is mostly achieved by an oocyst wall
that contains the extensively cross-linked Cryptosporidium outer
wall protein (COWP), a 165–175 kDa protein with cysteine-rich
C- and N-termini that generate a disulﬁde mesh in the wall [36].Other parasites such as Trypanosomatidae possess a well-devel-
oped glycocalix rich in GPI-anchored elements that can equally
hamper AMP access to the PM and decrease peptide efﬁciency. This
abundance of GPI-anchored components is imposed by the subpelli-
cular microtubule layer that runs beneath the PM and impairs integral
protein diffusion in the membrane plane other than at the apical end
(ﬂagellar pocket), where all membrane trafﬁc takes place [37].
In Leishmania promastigotes two major glycocalix components,
both anchored through GPI structures, can be differentiated: (i) the
lipophosphoglycan (LPG), an anionic oligosaccharide, and (ii) Gp63
(also named major surface proteinase or leishmaniolysin), a metallo-
proteinase of broad speciﬁcity. The strong anionic character of LPG
results from the so called repeat region, formed (in L. donovani) by the
disaccharide repeat [Gal(β 1,4)Man(α1-PO4→6)]n (n=16–30). A
calculation [38] established that 6×106 copies of LPG/cell covered
about 40% of the promastigote surface. LPG has been shown to provide
partial protection for L. donovani promastigotes against AMPs such as
magainin 2 and analogs; from the activity ratio vs. the R2D2 strain,
deﬁcient in the repeat region, a protection factor of 2 has been
assigned to LPG [39]. On the other hand, temporins A or B, having
smaller size (13 vs. 23 residues) and less cationic character (+2 vs.
+4.5 charge at neutral pH) thanmagainin 2, are equally active against
either strain, and likewise unaffected by the presence of other
oligosaccharides with a higher anionic character as heparin [40].
Similarly, bombinins H2 and H4, showed a similar activity towards
R2D2 and a poor inhibition by heparin [41].
The other Leishmania glycocalix component, metalloprotease
Gp63, with ca. 5×105 copies/cell in the promastigote [42], also exerts
a protective effect against AMPs, as shown by the fact that Gp63-
deﬁcient L. major promastigotes are twice more susceptible than the
wild type to pexiganan, an optimized magainin 2 analog [43].
The above observations aside, the protection afforded by the two
glycocalix components must not be viewed as a key factor in the
resistance strategies of Leishmania against AMPs. This is borne out by
the fact that axenic strains of the amastigote (intracellular) form of the
parasite are consistently more resistant than promastigotes [41,44],
despite their practically nil expression of LPG or Gp63 [45].
3.4. Challenges of intracellular parasitism
For Plasmodium, Leishmania, Trypanosoma cruzi, Toxoplasma or
Cryptosporidium, to cite the most relevant parasites in terms of human
health impact, pathogenesis in the vertebrate host is due to the
intracellular stage of the life cycle. This has obvious implications for any
potential application of AMPs in clinics, namely that evidence of lethal
activity on the intracellular stages is mandatory. While the require-
ment for intracellular activity appears to limit the applicability of AMPs
as antiparasitic agents, at the same time it opens the possibility of AMP
cooperation with the defensive mechanisms of the infected cell in
order to eliminate the pathogen. Despite the relative paucity of
research on AMPs in parasite–host cell systems, the substantial variety
of the data at hand makes a case-by-case approach advisable.
For malaria, the most extensive work on amphibian AMPs with
antiplasmodial activities has focused on the dermaseptins. On these,
twomajor classes with therapeutic potential and speciﬁcity have been
described: (i) those causing preferential lysis of infected over non-
infected erythrocytes, such as K4K20-S4 and K4S4(1–13)a [46], and (ii)
peptides with highly lytic activity on the parasite, regardless of the
parasitation stage, at concentrations innocuous for the erythrocyte,
such as the natural dermaseptin-S3 (DRS-S3) [47] or the N-terminally
acylated C3-K4S4(1–13)a and iC4-K4S4(1–13)a [48], and the aminoa-
cylated NC7-K4S4(1–13)a [49] (Table 2). For lytic peptides of this kind,
the question remains of how the peptide can reach the intracellular
parasite.
Some hallmarks of Plasmodium parasitism may provide clues on
how to achieve the required AMP intracellular targeting. In order to
Table 2
Synthetic analogs of amphibian peptides with antiprotozoal activity
Peptide Sequencea Protozoan specie (stage)b Microbicidal effect Comments References
Inhibition (%) [Peptide] (μM)
MSI-94 GIGKFLKKAKKFGKAFVKMKK-NH2 T. cruzi (epi) 50 100 [151]
(try) 50 64.8
Leishmania braziliensis
(pro)
20 100 [151]
Acanthamoeba polyphaga
(tph)
100 16 As minimal amoebicidal
concentration
[75]
MSI-103 KIAGKIAKIAGKIAKIAGKIA-NH2 A. polyphaga (tph) 100 12.1 q [75]
F5WMagainin2 GIGKWLHSAKKFGKAFVGEIMNS L. donovani (pro) 50 6.1 [39]
90 9.2
Magainin B GIGKFLHAAKKFAKAFVAEIMNS-NH2 Blastocystis hominis 100 200 [82]
Entamoeba histolytica
(tph)
90 20.2 [82]
T. cruzi (stage unknown) 100 40.4 [82]
MGH1 GIKKFLHIIWKFIKAFVGEIMNS L. donovani (pro) 50 2.4 [39]
90 4.3
MGH2 IIKKFLHSIWKFGKAFVGEIMNI L. donovani (pro) 50 0.9 [39]
90 1.0
Peptide Z
[D-Lys4,10,11,14, DPhe5,12,16]
GIGkfLHSAkkfGkAfVGEIMNS-NH2 Paramecium caudatum N100 As minimal disruptive
concentration
[139]
T. pyriformis N100 [139]
A. castellanii 100 12.2 [139]
Magainin H GIGKFLHSaKKFaKAFVaEIIMNS-NH2 B. hominis 0 200 [82]
E. histolytica (trp) 0 200 [82]
T. cruzi (stage unknown) Slight damage 200 [82]
Pexiganan GIGKFLKKAKKFGKAFVKILKK-NH2 L. amazonensis (pro) 30 100 [43]
Magainin G βAGIGKFLHSAKKFAKAFVAEIMNS-NH2 B. hominis 50 195 [82]
E. histolytica (tph) 90 20.2 [82]
DS1(1-29)-NH2 ALWKTMLKKLGTMALHAGKAALGAAADTI-NH2 L. major (pro) 50 2.3 [152]
K4K20S4 ALWKTLLKKVLKAAAKAALKAVLVGANA P. falciparum (tph) 50 0.2 Preferential lysis of
infected RBC
[46]
L. major (pro) 50 1.5 [9,79,141]
K4S4(1–13)a ALWKTLLKKVLKA-NH2 P. falciparum (tph) 50 3.3 Preferential lysis of
infected RBC
[46,48,49]
(rng) 50 7.6
L. major (pro) 50 9 [79]
C3-K4S4(1–13)a Propionyl-ALWKTLLKKVLKA-NH2 P. falciparum (trp) 50 4.3 Improved therapeutic index.
No discrimination between
infected and uninfected
human RBC
[48]
iC4-K4S4(1–13)a Isobutyryl-ALWKTLLKKVLKA-NH2 P. falciparum (tph) 50 3.8 q [48]
NC7-K4S4(1–13)a Aminoheptanoyl-ALWKTLLKKVLKA-NH2 P. falciparum (rng) 50 14.2 [49]
L. major (pro) 100 6.2 [94]
NC4-K4S4(1–13)a Aminobutyryl-ALWKTLLKKVLKA-NH2 L. major (pro) 100 6.2 [94]
a Small capitals stand for D-amino acids.
b Abbreviations: ama, amastigote; epi, epimastigote; gam, gamont; i.f., intracellular forms; mer, meront; ooc, oocyst; pro, promastigote; RBC, erythrocytes (red blood cell); sch:
schyzont; spo: sporozoite; rng, ring; tph, trophozoite; try, trypomastigote.
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and of transcriptional and translational activities, Plasmodium under-
takes extensive remodeling of the host cell. This involves a consider-
able increment in the membrane content of the infected erythrocyte,
with a ﬁve-fold rise in PL content over a non-infected cell; also the
formation of an intra-erythrocyte parasitophorous vacuole where the
parasite dwells, plus an extensive system of trans-membrane
communication between vacuole, cytoplasm and external medium
that includes the tubovesicular network, Maurer's clefts, and other not
yet fully unveiled transport systems [50,51]. A ﬂuorescent analog of
NC7-K4S4(1–13)a with antiplasmodial but no haemolytic activity
does not stain the infected erythrocyte but localizes on the PM of
Plasmodium and, more importantly, in the tubovesicular system of
the infected erythrocyte, suggesting a possible intra-erythrocytic
pathway for the peptide to reach the parasite [49].
Another parasite-induced modiﬁcation, partly related to the one
above, is a substantial modiﬁcation of the PM of the infected
erythrocyte. This affects, ﬁrst, the PM protein pattern; a secretome
of over 300 proteins, including transporters encoded by the parasite,
has been reported for the adaptation of the erythrocyte to P. falciparum
[52]. Second, andmore relevant from the AMP perspective, adaptationinvolves changes in PM physical structure. Among PL constituents, the
most signiﬁcant changes are in fatty acid composition [53] and
asymmetry; in the latter case, an increase in amino phospholipid
exposure in the outer leaﬂet of the infected erythrocyte can be
detected by chemical labeling [54]. Plasmodium also induces a drop in
the cholesterol: PL ratio of the PM [55]; streptolysin O, a cholesterol-
speciﬁc toxin, lyses preferentially non-infected vs. infected erythro-
cytes [56]. An increase in erythrocyte PM ﬂuidity has also been
described [57].
Altogether, these changes plus the in vitro data on liposome lysis
by AMPs, may presumably account for the enhanced susceptibility of
infected erythrocytes towards AMPs. Although conclusive proof of
their involvement in AMP-mediated erythrocyte lysis is still missing,
for AMPs such as the NK-lysin analog NK-2, the higher (infected vs.
non-infected) erythrocyte lysis rate is abrogated by preincubation
with annexin-V, a speciﬁc PS-binding protein, thus suggesting that
preferential exposure of this PL is a main factor in PM remodeling [58].
Cryptosporidium and Leishmania, the other two parasites with a
signiﬁcant number of studies with amphibian AMPs, infect metabo-
lically active cells with functional membrane trafﬁc. Some natural
amphibian AMPs reduce to various degrees the burden of intracellular
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develops a special type of relationship with the host cell, called
epicellular (i.e., intracellular but extra-cytoplasmic) parasitism,
characterized by the formation of a parasitophorous vacuole at the
apical end of epithelial intestinal cells, separated from the external
medium by a thin rim of plasma membrane, and feeding on the
cytoplasm of the host cell by formation of a feeder organelle [65].
Furthermore it has the capability to complete the full cycle in
extracellular manner, thus it is not an obligatory intracellular parasite.
How peptides are capable to affect the viability of such intracellular
parasites is not known.
Leishmania is the other paradigmatic model of intracellular
parasite, with a preference for macrophages, i.e., terminally differ-
entiated cells whose professional phagocytic and antigen-presenting
roles involves high metabolic activity and extensive membrane trafﬁc.
Among natural AMPs of amphibian origin, temporins A and B are
known to curb proliferation of the intracellular amastigote [44], which
dwells inside a parasitophorus vacuole with late endosome–lysosome
features [66].
While genomic data reveal extensive transcriptional reprogram-
ming of the macrophage on account of Leishmania infection [67,68], in
contrast to Plasmodium (see above), no conclusive evidence on how
parasite infection affects AMP killing of intracellular parasites has
been found. An increase in PM ﬂuidity for macrophages infected with
L. donovani, which perhaps may inﬂuence AMP lysis, has been
reported; interestingly, it is reverted by incubation with cholesterol-
containing liposomes [69], suggesting changes in its content.
Other parasiticidal effects of AMPs on intracellular protozoa would
appear to derive not from a direct microbicidal effect, but from
peptide-induced immunomodulatory activities on the macrophage.
For instance, temporin A and some analogs are chemotactic for human
monocytes, macrophages and neutrophils through the FPRL-1
receptor [70] and dermaseptin-S9 (DRS-S9) also causes chemotaxis
although in this case the microbicidal and chemotactic activities are
dependent on the aggregational state of the peptide [71]. For its part,
dermaseptin-S1 (DRS-S1) is able to induce in human neutrophils
production of reactive oxygen species (ROS), toxic for many
intracellular parasites [72].
3.5. Synergy of amphibian AMPs with other chemotherapeutic
compounds
The ability of AMPs to synergize with other AMPs or other
antibiotic agents is well established for bacteria. Synergism among
AMPs for the same organism and anatomical location underlines the
efﬁcacy of innate immunity in controlling pathogen dissemination, as
demonstrated for dermaseptins, temporin B and L [73], or by the
synergism between PGLa and magainin 2 either as an heterodimer
artiﬁcial presentation or formed spontaneously when inserted into
the membrane [74].
Cryptosporidium has been widely used as a target for diverse
amphibian AMP combinations (Table 3). Thus, ranalexin shows anTable 3
Antiprotozoal activity of amphibian AMPs in combination with other antibiotics
Combination (A+B) Protozoa (stage)a Microb
(A, B)
Ranalexin (50 μM)+magainin II (50 μM) C. parvum (mer+gam) 42; 3
Ranalexin (50 μM)+Azithromycin (8 μg/mL) 42; 1
Ranalexin (30 μM)+lasalocid (2 μg/mL) C. parvum (mer+gam) 33.8; 7
Buforin 20 μM+Azithromycin 8 μg/mL C. parvum (mer+gam) 55.7; 3
Buforin 20 μM+Minocycline 8 μg/mL C. parvum (mer+gam) 54.4; 2
MSI-94 10 μM+200 μg/mL AgNO3 A. polyphaga (tph) 92; 8
MSI-94 10 μM+25 μg/mL Ketoconazol A. polyphaga (tph) 92; 1
MSI-103 9.7 μM+200 μg/mL AgNO3 A. polyphaga (tph) 100; 9
a Abbreviations: cyt, cyst; gam, gamont; mer, meront; tph, trophozoite.additive outcome with Lasocid, a polyether ionophore that causes PM
depolarization [64], with azithromycin [61,64] or clarithromycin [61],
macrolide antibiotics inhibiting protein synthesis. Ranalexin also
synergizes with rifanbutin and rifampin [61], two antibiotics of the
ansa family that in bacteria act as transcription inhibitors but whose
targets in Cryptosporidium remain unknown, and with magainin 2 and
amiloride, a diuretic that acts by blocking the epithelial sodium
channel [62]. Interestingly, ranalexin-1CB shows additive though not
synergic behavior when given together with other membrane-active
AMPs such as indolicidin or magainin 2 [61].
For its part, magainin 2 in combination with some acanthamoe-
bicidal agents (silver nitrate, ketoconazole, propamidine isethionate,
gramicidin S or neomycin sulfate) showed enhanced therapeutic
outcome against the amoeba form, whereas the silver nitrate com-
bination was the only one active against the cyst form [75] (Table 3).
4. Optimization of the antiprotozoal activity of amphibian AMPs
Since the very discovery of amphibian AMPs, SAR studies have
pursued the double goal of unraveling the structural basis of their
activity and speciﬁcity [76] and developing novel and attractive
clinical chemotherapeutic alternatives [77]. The most paradigmatic
example in this respect is pexiganan acetate, a magainin analog that
reached phase III trial. As with AMPs from other biological sources,
linear peptides have received special attention due to their easier
synthetic accessibility [1,2,78]. This section will focus on the main
structural features used to modulate the anti-protozoan activities of
amphibian AMPs.
4.1. Cationic character
A minimal cationic character is widely assumed to be a
requirement for recognition of the different charge densities
between protozoan parasites and their hosts. From this it follows
that an increase in the overall positive charge should improve the
microbicidal activity of AMPs on parasites. For instance, a dual
replacement (M4K and N20K) in dermaseptin-S4 (DRS-S4), with a
gain of two positive charges, translated into a gain of leishmanicidal
speciﬁcity [9]. A similar approach enhanced the antiplasmodial [46]
activities of the parental peptide, together with a signiﬁcant decrease
in hemolytic activity [46,79]. It has also been found, however, that
once an upper threshold of cationic charge is reached, the peptide
can become irreversibly stuck to the membrane or to the anionic
glycocalix of the pathogen, preventing access to the membrane or
adoption of an active conformation [80], and causing a loss of
speciﬁcity due to enhanced cytotoxicity [81]. A molecular inter-
pretation of these adverse results is that repulsion between peptide
monomers (see Section 2) shortens the half-life of the forming pore
[80]. Indeed, the cationicity requirement would appear to be not
simply quantitative but topological. Thus for buforin 2, an α-helical
peptide active on Cryptosporidium [34,59,60], the local accumulation
of positive charges required for membrane translocation inducesicidal effect (%) Commentsa Reference
(A+B)
5 93.6 Additive effects [61]
6 74.4 q [64]
0.3 100 Additive effect [64]
2.1 94.4 q [60]
4.6 90.5 q [60]
0 100 Combination showed full amoebicidal effect [75]
00 100 q [75]
1.6 100 tph and cyt elimination [75]
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peptide uptake [19].
4.2. Minimization of active structures
Sequence shortening of AMPs while retaining signiﬁcant activity
and speciﬁcity is one of the obviously desirable goals in the
chemotherapeutic development of AMPs, with a view to reducing
production costs and minimizing the risks of a large peptide inducing
an unwanted immune response. A representative example in this
direction is the systematic truncation of K4K20S4, a “cationized”
version of dermaseptin-S4 with lower tendency to aggregate than the
native peptide. From the initial 27-mer, a tridecapeptide K4S4(1–13)a
with an above 30-fold decrease in cytotoxicity was derived, while
leishmanicidal [79] and antiplasmodial activities [46] decreased less
than one log order.
4.3. Overall peptide structure
A high α-helix content for peptide binding to the membrane has
also been assumed to be an essential requirement for AMP activity on
most targets, including parasitic Protozoa [82]. Thus, short derma-
septin-S4 analogs active on Leishmania and Plasmodium such as K4S4
(1–13)a or K4S4(1–16)a were designed so as to preserve a strong α-
helical conformation [79]. However, the ﬁnding that pathogen
permeabilization can be achieved by poorly structured AMPs has
challenged this hypothesis [11]. For instance, dermaseptin-S3 (DRS-
S3), selective on Plasmodium over erythrocytes [47], is found by NMR
to be unstructured, thus questioning the α-helix requirement as
essential for strong parasiticidal effect [83].
A further concern in the design of optimized versions of AMPs is
the control of peptide aggregation in solution, a somehow intrinsic
trend of amphipathic structures with fairly extensive hydrophobic
surfaces that favor intermolecular association. While aggregation has
been reported to hinder effective membrane binding and eventually
impair the killing of bacteria with intact external barriers, for
protozoan targets the evidence in this respect is a bit ambiguous.
Thus, on the one hand, magainin analogs suspected of aggregation,
such as MG-H1, show diminished leishmanicidal activity relative to
monomeric analogs [39]. On the other hand, aggregation-prone
dermaseptin-S4 analog K4K20S4 appears to enjoy unhindered access
to the membrane despite the compact glycocalix of Leishmania. Also,
the higher antiplasmodial activity of dermaseptin-S4 (aggregated) vs.
dermaseptin-S3 (monomeric) has been accounted by the binding of
peptide aggregates causing a substantial concentration at the
membrane insertion point [47]. Along similar lines, preformed
aggregates of the synthetic KL diastereomeric peptide substantially
increased the poor fungicidal activity of themonomeric form [84], and
suprastructures mimicking α-helical bundles showed enhanced
hemolytic activity over the monomer version [85]. In conclusion, it
would appear that the issue of peptide self-association does not lend
itself to a uniform, simplistic approach, but is best approached on a
case-by-case basis, where the different variables (peptide aggregation
state, membrane structure and superstructure) are addressed.
A minor but often not trivial contribution to peptide overall
structure is the nature of the C-terminal group. A substantial fraction
of the natural AMPs are C-terminally amidated, as a result of post-
translational decarboxylation of a precursor with an additional Gly
residue. Many AMP analogs are similarly C-terminally amidated, often
for additional synthetic considerations. Amidation affords partial
protection against endopeptidases, increases the positive charge of
the peptide (vs. a free carboxyl version), and enhances the α-helical
intrinsic dipole, thereby stabilizing any potential helical conformation.
These factors, whatever their respective contribution, usually bear
favorably on AMP activity. For instance, amidation of short derma-
septin-S4 analogs K4K20S4 and K4S4(1–16) increases the activity onPlasmodium by one log order [79,86] vs. a 5-fold increase in hemolytic
activity, thus achieving a moderate increase in selectivity. For
dermaseptin-S3, amidation induces a substantial increase in peptide
structuration [87] and a concomitant increase in microbicidal activity
on bacteria and fungi [88].
Several natural AMPs contain a D-amino acid residue at a single
position [89], including the bombinins H4 and H7 from Bombina
species, in which D-allo-isoleucine and D-leucine, respectively, are
incorporated at position 2 [90]. Comparison of bombinin H4 with its
epimer bombinin H2 (l-Ile at position 2) shows better leishmanicidal
activity for the former [41], which in a molecular dynamics study
appears to possess a broader conformational repertoire in solution
than H2. Analysis of the membrane-bound peptides by ATR-FTIR
shows H4 to be slightly more α-helical than H2, regardless of
membrane composition, while in an NMR study the differences
between the two epimers are conﬁned to the ﬁrst four residues,
postulated to determine the aggregation propensity. In model
membranes mimicking the Leishmania PM composition, partial
aggregation of H2 but not of H4 has been detected, presumably
impairing pore formation and hence Leishmania killing (for a detailed
discussion see [91]). A similar amyloidogenic behavior on the
membrane has also been recently described for dermaseptin-S9
(DRS-S9) [71].
Synthetic diastereomers, in which D-amino acids replace native L-
residues at designed positions, have been promoted by the group of
Shai as a tool to assess the role of conformation in the activity of α-
helical peptides. The impact of this modiﬁcation on the global peptide
conformation depends on the hydrophobicity of the region where the
substitutions take place [11]. An evenly and extensive substitution on
magainin leads to a substantial loss of activity of magainin 2 on T. cruzi
[82].
4.4. Acylation
Most SAR studies on AMPs routinely include residue replace-
ments altering the charge or hydrophobicity at a given position or
region of the sequence. As such changes need involve modiﬁcation
in side chain structure, they may undesirably impinge on other
peptide parameters as well. An alternative approach to increasing
the hydrophobicity of an AMP is conjugation to a hydrophobic
moiety (usually a fatty acid) at the amino end (see Ref. [92] for
acylation in internal positions of an AMP active on Leishmania). In
this way the primary structure and its associated properties other
than hydrophobicity are largely preserved. Among amphibian
AMPs, acylation has been studied on magainin 2 [93] and
dermaseptin-S4 (DRS-S4) analogs [46,48,83,94], although only the
latter have been tested on Protozoa. Acylation neutralizes the
positive charge at the α-amino group (an exception being the
acylation with a lipophilic aminoacyl moiety [83,94]), and partially
protects against proteolytic attack, as observed for the dermasep-
tin-S4 analogs NC12-K4S4(1–13)a and C12-K4S4(1–13)a [94] and for
palmitoyl-magainin 2 [93]. The acyl chain also constitutes a
hydrophobic template which may favor either structuration or
aggregation of the peptide. The effect of acyl chain length on these
two parameters has been studied in detail for magainin 2 and the
dermaseptin-S4 analog K4S4(1–13)a. While in the ﬁrst case, a bell-
shaped effect for aggregation vs. chain length was observed [93],
for K4S4(1–13)a the monomeric status was maintained up to the
miristoyl (C12) [83,94], further lengthening promoting peptide
aggregation. The aggregation propensity may be partly reverted
by aminoacylation: the NC12-K4S4(1–13)a analog [94] shows the
same aggregation state as the unacylated parental peptide, even
higher than that produced with the equivalent acylation [83]. In
the NC12 analog these modiﬁcations bring about an increase in
structuration and amphipaticity of the N-terminal region [83].
Interestingly, for magainin 2 acylation does not change the parallel
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chain must be inserted perpendicular to the bilayer plane [93].
The acylated analogs of K4S4(1–13)a showed an increase in
hemolysis for acyl group length over ﬁve carbons [48,94], whereas
the leishmanicidal and antiplasmodial activities levelled off at
N-pentanoyl- and N-hexanoyl-analogs respectively [48,94]. For the
later activity, the best analogs correspond to propionyl-K4S4(1–13)a
and isobutiryl-K4S4(1–13)a, not only because of their high selectivity
index, but for their selective lysis of the intracellular Plasmodium but
not of the PM of the infected erythrocyte [48]. Interestingly, the
inclusion of an ω-amino group in the acyl group, causes a lower
hydrophobicity, an additional positive charge and reduction of
aggregation; furthermore aminoacylated analogs were less hemolytic
than the parent up to NC7. NC4-K4S4(1–13)a, the least toxic analog, has
an LC50 for hemolysis higher than 100 μMwhereas for the parent K4S4
(1–13)a is 50 μM [94]; furthermore this analog possesses the higher
selectivity index for Leishmania [94].
5. Perspectives on amphibian AMPs and Protozoa
As all pluricellular organisms, Amphibia endure parasitism and
commensalism by a wide variety of Protozoa (reviewed by [95]). For
the approximately 4000 amphibians described by 1998, over 200
species of parasites and microbiota were reported, including human
parasites such as kinetoplastids [96], sporozoans [95] or amoebazoans
[97]. Information on amphibian pathologies is mostly limited to those
in amphibian husbandry [98] rather than in the natural habitat. Even
less is known about the protection accorded to Amphibia by AMPs
active on protozoan, nor about the potential role of those pathogens as
AMP inducers [99]. A recent study, spurred by the global decline of
Amphibia, has focused on chytridiomycosis, an infection by the fungus
Batrachochytrium dendrobatidis, and on the role of AMPs in such a
context [100].
As it is, the biodiversity of Amphibia, along with the notion that
each species may possess a distinct set of AMPs [101] whose even
minute structural variations may modulate activity on different
microorganisms [88], make this animal class a virtually inexhaustible
source of AMP leads. The generalized application of proteomics
[102,103] and transcriptomics [104,105] technologies is likely to
expand even further the set of natural AMPs to be tested. In fact, the
current number of amphibian AMPs is arguably underestimated, for at
least two reasons: (i) the quest for amphibian AMPs has focused
almost exclusively on cutaneous secretions, mostly ignoring other
anatomical locations [106,107]; (ii) the increasing evidence of
intracellular targets, a step ahead of relatively unspeciﬁc membrane
permeation [8], is likely to broaden the roster of amphibian AMPs.
Within this latter group, buforin 2 has acquired notoriety by its DNA-
binding properties, both in bacteria [108] and in tumor cells [109].
Other amphibian AMPs formerly assumed to act by mere membrane
permeation have on closer inspection seen to induce apoptosis (i.e., a
necrotic rather than an apoptotic scenario); these include brevinin-2R
on tumoral cells [110], dermaseptin-S3(1–16) on yeast [111,112],
magainin 2 [112] on yeast, or pexiganan on Leishmania [43].
As for protozoan targets, the feasibility of AMPs as antiparasitic
chemotherapeutical alternative has been dealt with in previous
sections, noting as well their efﬁcacy in situations where speciﬁcity
is at a premium, such as intracellular Plasmodium, Cryptosporidium or
Leishmania, or cloroquine-resistant Plasmodium strains [46]. Other
protozoans acting as extracellular parasites in vertebrate hosts, such
as Trichomonas vaginalis, Giardia lamblia, or African trypanosomes,
have been shown to be susceptible to at least one type of AMP.
Most if not all of the structural modulation strategies used in the
therapeutic optimization of amphibian AMPs against non-protozoan
pathogens [76,113,114], including cyclization [115], dimerization
[116], hybridization with other AMP sequences (amphibian or not)
[117–119], use of non-proteinogenic amino acids [113], or variousmodes of stereoisomeric intervention [116,120] can also be tested on
protozoan targets. The availability of fast systematic AMP screens on
parasites [121] is a valuable tool in the development of anti-protozoan
candidates.
It may be argued that the main caveat for a future extensive use of
AMPs in anti-parasite or, in general, anti-infectious chemotherapy
possibly lies in the production costs. Though accurate if a strict
comparison between conventional small molecule drugs and AMPs is
enforced, the above notion needs to be properly qualiﬁed. For small
size AMP candidates preferably accessible by chemical synthesis, the
SAR strategies discussed in Section 4 above, aimed at size reduction
and proteolytic stabilization, can have a favorable impact on cost
reduction. For longer sequences, recombinant and other (e.g., plant)
production alternatives are advisable, if the foreseeable toxicity of the
end product can somehow be averted. A number of examples of
recombinant production of amphibian AMPs have been described and
reviewed [122].
AMP combination therapy with classical antiparasitic drugs is a
further option. In this regard, a seemingly attractive approach is one
that exploits “crisis solutions” for lipid biosynthesis undertaken by
protozoa in the face of drug pressure. Those include changes in PL
composition and orientation, or in type and content of sterol [10,123–
125]. Evidently, drugs affecting those systems are likely to modulate
the outcome of AMP action. Selected ﬁndings supporting this
approach include the shifts (e.g., reversion of the PC:PE ratio) in T.
cruzi membrane PL composition caused by ajoene [126]; also on T.
cruzi, the effect on sterol biosynthesis of inhibitors such as azasterols
[127], the triazole UR-9825 [128], or miltefosine (hexadecylpho-
sphocholine) [129], which causes similar effects on Leishmania
donovani [130]. For Trypanosomatidae, inhibition of ergosterol
biosynthesis can backﬁre on AMP-based treatments, since the natural
sterol is at least partially replaced by cholesterol from the host [131],
or by accumulation of ergosterol precursors such as lanosterol, as
found for L. mexicana promastigotes [132]. Either solution turns out to
be detrimental for the activity of AMPs such as temporin L, for which a
marked inhibition of membrane insertion is noted [26]. For its part,
miltefosine resistance in L. donovani promastigotes results in PLs with
fewer unsaturations and shorter chains, altogether leading to a
decrease in PM ﬂuidity [133]; a similar increase in saturated fatty
acid chains was observed for T. cruzi upon treatment with ketocona-
zole [127] or ajoene [126].
Finally, other effects include an increase in the PS content of T. cruzi
brought about by the aforesaid RU-9825 [128], or the simultaneous
decrease in PS and increase in PI achievedby the 22, 26-azasterol [134];
the same drug on Plasmodium causes an increase in PS content [135].
Related applications of amphibian and other AMPs vs. Protozoa
include the elimination of T. cruzi contamination in blood transfusion,
a serious concern in blood banks, or the development of transgenic
arthropod vectors able to impair parasite transmission, as shown by
the direct inoculation of magainin in Anopheles [136].
It will be clear from the previous exposition that, in the realm of
parasite–peptide relationships, the questions still far outnumber the
answers, to a signiﬁcant extent because of the neglected target
condition of parasites, and ensuing reasons already alluded to in the
Introduction. Even so, it is likely that novel AMPs for parasites will be
developed, beneﬁting from cost reductions achieved in the pharma-
cological development against more economically valuable patho-
gens, a situation not unlike that observed in recent years for drugs
such as miltefosine or amphotericin, initially developed for anti-
tumoral and antifungal applications [137].
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